This clinical trial is focused on studying a type of cancer called metastatic colorectal cancer, which is a form of cancer that starts in the colon or rectum and spreads to other parts of the body. Specifically, the study is looking at patients with certain genetic features known as dMMR (deficient mismatch repair) and MSI (microsatellite instability). These features can affect how cancer grows and responds to treatment.

The trial is testing two medications, nivolumab and ipilimumab, which are given together as a combination treatment. Nivolumab, also known by its code name BMS936558, and ipilimumab, also known as BMS734016, are both types of drugs called immunotherapies. They work by helping the body’s immune system recognize and attack cancer cells more effectively. The purpose of the study is to evaluate the safety and effectiveness of these two combination treatments over a period of 24 weeks.

Participants in the study will receive the medications through an infusion, which means the drugs are given directly into the bloodstream through a vein. The study will monitor how well the treatments work and any side effects that may occur. The goal is to understand how these treatments can help manage metastatic colorectal cancer with dMMR and MSI features, providing valuable information for future cancer care.